The where and when of T cell regulation in transplantation

Trends in Immunology

Volumn 34, Issue 3, 2013, Pages 107-113

  Issa, Fadi ^a   Robb, Renee J ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bone marrow transplantation; Regulatory T cells; Solid organ transplantation

Indexed keywords

ALLOGRAFT; ALLOIMMUNITY; CELL MIGRATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOID TISSUE; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY MECHANISM; REVIEW; SOLID ORGAN TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; HUMANS; MICE; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 84875270130     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.11.003     Document Type: Review

References (67)

1. Issa F., Wood K.J. Translating tolerogenic therapies to the clinic - where do we stand?. Front. Immunol. 2012, 3:254.
2. Wood K.J., et al. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 2012, 12:417-430.
3. Issa F., Wood K.J. CD4+ regulatory T cells in solid organ transplantation. Curr. Opin. Organ Transplant. 2010, 15:757-764.
4. Wood K.J., Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012, 93:1-10.
5. Sagoo P., et al. Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation. Front. Immunol. 2012, 3:184.
6. Carvalho-Gaspar M., et al. Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J. Immunol. 2008, 180:6640-6648.
7. Ring S., et al. CD4+ CD25+ regulatory T cells suppress contact hypersensitivity reactions by blocking influx of effector T cells into inflamed tissue. Eur. J. Immunol. 2006, 36:2981-2992.
8. Tomura M., et al. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J. Clin. Invest. 2010, 120:883-893.
9. Ding Y., et al. Regulatory T cell migration during an immune response. Trends Immunol. 2012, 33:174-180.
10. Kingsley C.I., et al. Transplantation tolerance: lessons from experimental rodent models. Transpl. Int. 2007, 20:828-841.
11. Lee M.K., et al. T-reg mediated suppression of the allograft response in the draining lymph node. Transplantation 2006, 81:1063-1066.
12. Karim M., et al. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005, 105:4871-4877.
13. Long E.T., et al. Alpha-1,2-mannosidase and hence N-glycosylation are required for regulatory T cell migration and allograft tolerance in mice. PLoS ONE 2010, 5:e8894.
14. Zhang N., et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009, 30:458-469.
15. Ermann J., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
16. Nadig S.N., et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 2010, 16:809-813.
17. Ochando J.C., et al. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J. Immunol. 2005, 174:6993-7005.
18. Wysocki C.A., et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005, 106:3300-3307.
19. Ochando J.C., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 2006, 7:652-662.
20. Rudensky A.Y., Campbell D.J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J. Exp. Med. 2006, 203:489-492.
21. Nguyen V.H., et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007, 109:2649-2656.
22. Yan Z., et al. Extracellular redox modulation by regulatory T cells. Nat. Chem. Biol. 2009, 5:721-723.
23. Borsellino G., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
24. Deaglio S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
25. Dudda J.C., et al. Foxp3+ regulatory T cells maintain immune homeostasis in the skin. J. Exp. Med. 2008, 205:1559-1565.
26. Sather B.D., et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J. Exp. Med. 2007, 204:1335-1347.
27. Montane J., et al. Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. J. Clin. Invest. 2011, 121:3024-3028.
28. Erhardt A., et al. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J. Immunol. 2011, 186:5284-5293.
29. Villares R., et al. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur. J. Immunol. 2009, 39:1671-1681.
30. Yamazaki T., et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J. Immunol. 2008, 181:8391-8401.
31. Hadis U., et al. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity 2011, 34:237-246.
32. Waldmann H., et al. Regulation and privilege in transplantation tolerance. J. Clin. Immunol. 2008, 28:716-725.
33. Lee I., et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med. 2005, 201:1037-1044.
34. Issa F., et al. Role of T cells in graft rejection and transplantation tolerance. Expert Rev. Clin. Immunol. 2010, 6:155-169.
35. Kendal A.R., et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J. Exp. Med. 2011, 208:2043-2053.
36. Waldmann H., et al. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol. Rev. 2006, 212:301-313.
37. Lennon G.P., et al. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 2009, 31:643-653.
38. Koch M.A., et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 2009, 10:595-602.
39. Zheng Y., et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 2009, 458:351-356.
40. Chaudhry A., et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
41. Hester J., et al. Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. Transplantation 2011, 91:744-750.
42. Huber S., et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011, 34:554-565.
43. Duhen T., et al. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector TH cells. Blood 2012, 119:4430-4440.
44. Lim H.W., et al. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J. Immunol. 2006, 177:840-851.
45. Siewert C., et al. Induction of organ-selective CD4+ regulatory T cell homing. Eur. J. Immunol. 2007, 37:978-989.
46. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin. Hematol. 2006, 43:3-10.
47. Blazar B.R., et al. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 2012, 12:443-458.
48. Koyama M., et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat. Med. 2012, 18:135-142.
49. Toubai T., et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood 2012, 119:3844-3853.
50. Beres A.J., et al. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J. Immunol. 2012, 189:464-474.
51. Robb R.J., et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood 2012, 119:5898-5908.
52. Sawamukai N., et al. Cell-autonomous role of TGFbeta and IL-2 receptors in CD4(+) and CD8(+) inducible regulatory T-cell generation during GVHD. Blood 2012, 119:5575-5583.
53. Shin H.J., et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011, 118:2342-2350.
54. Rowe V., et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006, 108:2485-2492.
55. Murphy S., Nguyen V.H. Role of gut microbiota in graft-versus-host disease. Leuk. Lymphoma 2011, 52:1844-1856.
56. Jenq R.R., et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J. Exp. Med. 2012, 209:903-911.
57. Eriguchi Y., et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood 2012, 120:223-231.
58. Naik S., et al. Compartmentalized control of skin immunity by resident commensals. Science 2012, 337:1115-1119.
59. Brunstein C.G., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
60. Feng G., et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci. Transl. Med. 2011, 3:83ra40.
61. Hippen K.L., et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci. Transl. Med. 2011, 3:83ra41.
62. Sagoo P., et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 2011, 3:83ra42.
63. Di Ianni M., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
64. Koreth J., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 2011, 365:2055-2066.
65. McMurchy A.N., et al. Moving to tolerance: clinical application of T regulatory cells. Semin. Immunol. 2011, 23:304-313.
66. Hester J., et al. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am. J. Transplant. 2012, 12:2008-2016.
67. Francis R.S., et al. Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur. J. Immunol. 2011, 41:726-738.